Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study

BACKGROUND: Rituximab is used for the treatment of active rheumatoid arthritis. In the present study, we examined the long-term flare risk and safety of reduced doses of rituximab. PATIENTS-METHODS: This was a prospective, observational, single-center study of patients starting rituximab on standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertsias, Antonios, Avgoustidis, Nestor, Papalopoulos, Ioannis, Repa, Argyro, Kougkas, Nikolaos, Kalogiannaki, Eleni, Bertsias, Georgios, Flouri, Irini, Sidiropoulos, Prodromos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161491/
https://www.ncbi.nlm.nih.gov/pubmed/35655317
http://dx.doi.org/10.1186/s13075-022-02826-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161491/
https://www.ncbi.nlm.nih.gov/pubmed/35655317
http://dx.doi.org/10.1186/s13075-022-02826-6

Ejemplares similares